FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897515101> ?p ?o ?g. }

• W2897515101 endingPage "2628" @default.
• W2897515101 startingPage "2619" @default.
• W2897515101 abstract "Abstract Transplant-associated thrombotic microangiopathy (TA-TMA), a complication of hematopoietic cell transplant (HCT), is associated with significant morbidity and mortality. The pathophysiology and overlap of TA-TMA with other posttransplant complications such as graft-versus-host disease (GVHD) is poorly understood. We retrospectively identified cases of TA-TMA among patients with grade 3/4 gastrointestinal (GI) GVHD, reviewed intestinal biopsy specimens, and performed correlative testing of biomarkers associated with TA-TMA. TA-TMA was more common in patients with steroid-refractory GVHD compared with steroid-responsive GVHD (79.3% vs 42.1%; P = .001). Among patients surviving 100 days post-HCT, 1-year survival from day 100 was significantly better for patients who had not developed TA-TMA in the first 100 days (69.5% vs 36.7%; P &lt; .001). Only 1 of 7 proposed TA-TMA histology criteria (mucosal hemorrhage) differed significantly based on GVHD steroid response. In multivariable modeling, steroid-refractory GVHD was a risk factor for development of TA-TMA (hazard ratio, 3.09; 95% confidence interval, 1.68-5.67; P &lt; .001). There were no differences in complement activation at GVHD onset; however, 2 to 6 weeks later, patients with TA-TMA had higher levels of BBPlus and C5b-9, markers of alternative and terminal pathway activation (BBPlus: median, 600 vs 209.3 ng/mL; P = .0045) (C5b-9: median, 425.9 vs 258.4 ng/mL; P = .029). TA-TMA is associated with poor overall survival (OS) following HCT and may be detected early by histologic findings and may be differentiated from GVHD by measurement of alternative and terminal complement pathway activation. It is unknown whether treatment of TA-TMA will improve survival in steroid-refractory GVHD." @default.
• W2897515101 created "2018-10-26" @default.
• W2897515101 creator A5000164789 @default.
• W2897515101 creator A5001345657 @default.
• W2897515101 creator A5003367392 @default.
• W2897515101 creator A5007847102 @default.
• W2897515101 creator A5010245035 @default.
• W2897515101 creator A5023917898 @default.
• W2897515101 creator A5024996698 @default.
• W2897515101 creator A5028145044 @default.
• W2897515101 creator A5031866104 @default.
• W2897515101 creator A5032065932 @default.
• W2897515101 creator A5033734703 @default.
• W2897515101 creator A5044663373 @default.
• W2897515101 creator A5046091655 @default.
• W2897515101 creator A5053638396 @default.
• W2897515101 creator A5058362903 @default.
• W2897515101 creator A5064150576 @default.
• W2897515101 creator A5072361065 @default.
• W2897515101 creator A5072835425 @default.
• W2897515101 creator A5078508615 @default.
• W2897515101 creator A5082516137 @default.
• W2897515101 date "2018-10-16" @default.
• W2897515101 modified "2023-10-18" @default.
• W2897515101 title "Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD" @default.
• W2897515101 cites W1566551321 @default.
• W2897515101 cites W1596317162 @default.
• W2897515101 cites W1689714760 @default.
• W2897515101 cites W1859210543 @default.
• W2897515101 cites W1950935999 @default.
• W2897515101 cites W1993215990 @default.
• W2897515101 cites W1995090169 @default.
• W2897515101 cites W2008458556 @default.
• W2897515101 cites W2009737338 @default.
• W2897515101 cites W2018433489 @default.
• W2897515101 cites W202428841 @default.
• W2897515101 cites W2038815061 @default.
• W2897515101 cites W2038876519 @default.
• W2897515101 cites W2042844369 @default.
• W2897515101 cites W2044072865 @default.
• W2897515101 cites W2044949230 @default.
• W2897515101 cites W2045959749 @default.
• W2897515101 cites W2046465273 @default.
• W2897515101 cites W2052605694 @default.
• W2897515101 cites W2071176203 @default.
• W2897515101 cites W2071824774 @default.
• W2897515101 cites W2085290177 @default.
• W2897515101 cites W2091209603 @default.
• W2897515101 cites W2093903773 @default.
• W2897515101 cites W2105179089 @default.
• W2897515101 cites W2112756201 @default.
• W2897515101 cites W2117803220 @default.
• W2897515101 cites W2118510193 @default.
• W2897515101 cites W2138131568 @default.
• W2897515101 cites W2141010787 @default.
• W2897515101 cites W2143258371 @default.
• W2897515101 cites W2150192501 @default.
• W2897515101 cites W2150471755 @default.
• W2897515101 cites W2152313784 @default.
• W2897515101 cites W2153187872 @default.
• W2897515101 cites W2156089995 @default.
• W2897515101 cites W2158889697 @default.
• W2897515101 cites W2159057750 @default.
• W2897515101 cites W2163847512 @default.
• W2897515101 cites W2175868602 @default.
• W2897515101 cites W2175887431 @default.
• W2897515101 cites W2285060053 @default.
• W2897515101 cites W2326205797 @default.
• W2897515101 cites W2343260633 @default.
• W2897515101 cites W2404639369 @default.
• W2897515101 cites W2538067145 @default.
• W2897515101 cites W2603138540 @default.
• W2897515101 cites W2611256748 @default.
• W2897515101 cites W2717271878 @default.
• W2897515101 cites W2726673692 @default.
• W2897515101 cites W2736218182 @default.
• W2897515101 cites W2736685273 @default.
• W2897515101 cites W2743394197 @default.
• W2897515101 cites W2753099642 @default.
• W2897515101 cites W2754136467 @default.
• W2897515101 cites W2766122872 @default.
• W2897515101 cites W2782986513 @default.
• W2897515101 doi "https://doi.org/10.1182/bloodadvances.2018020321" @default.
• W2897515101 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6199668" @default.
• W2897515101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30327370" @default.
• W2897515101 hasPublicationYear "2018" @default.
• W2897515101 type Work @default.
• W2897515101 sameAs 2897515101 @default.
• W2897515101 citedByCount "46" @default.
• W2897515101 countsByYear W28975151012019 @default.
• W2897515101 countsByYear W28975151012020 @default.
• W2897515101 countsByYear W28975151012021 @default.
• W2897515101 countsByYear W28975151012022 @default.
• W2897515101 countsByYear W28975151012023 @default.
• W2897515101 crossrefType "journal-article" @default.
• W2897515101 hasAuthorship W2897515101A5000164789 @default.
• W2897515101 hasAuthorship W2897515101A5001345657 @default.
• W2897515101 hasAuthorship W2897515101A5003367392 @default.

• next